Spondyloarthropathies News

Among a large cohort of patients with psoriasis, researchers found around 20% had an immune-mediated inflammatory disease develop before psoriasis onset and 14% had one develop after psoriasis onset, according to a study using data from the Danish National Patient Registry.

ATLANTA — Certolizumab pegol and bimekizumab were associated with improvements ranging from work productivity to disease activity in patients with spondyloarthritic conditions, according to findings presented in three abstracts at ACR/ARP 2019.

ATLANTA — Ixekizumab combined with conventional background medication is superior to both conventional background medication alone and placebo in improving signs, symptoms and inflammation based on MRI among patients with nonradiographic axial spondyloarthritis, according to data presented at ACR/ARP 2019.

ATLANTA — A daily regimen of 15 mg upadacitinib was significantly more effective than placebo in improving signs, symptoms, function and imaging among patients with active ankylosing spondylitis, according to the presenter at ACR/ARP 2019.

ATLANTA — The use of either non-TNF inhibitor biologics or tofacitinib for chronic inflammatory diseases during pregnancy did not significantly increase risk for serious infections among infants, according to findings presented at the 2019 ACR/ARP Annual Meeting.

ATLANTA — A vast majority of patients with a cross-section of rheumatic diseases reported that pain, fatigue and mental health issues were those they would like researchers to track, according to a speaker at ACR/ARP 2019.

ATLANTA — Rheumatologists need to suspect inflammatory bowel disease more often in patients who present with joint pain, particularly in the presence of other clues, such as changes in bowel habits, bloody stool and unexplained weight loss, according to a presenter at ACR/ARP 2019.

ATLANTA — Nearly one-third of primary care providers who treat patients with arthritis failed to follow Exercise Is Medicine guidance for physical activity, according to data presented at ACR/ARP 2019.

Rheumatology patients treated with interleukin inhibitors have an increased risk for serious infections, opportunistic infections and cancer, according to data published in JAMA Open Network.

The majority of physical therapists can accurately distinguish between inflammatory and noninflammatory arthritis and understand the importance of correct and prompt referrals to a rheumatologist for suspected inflammatory conditions, according to survey results published in Arthritis Care & Research.